[go: up one dir, main page]

CN107011138B - A kind of preparation method of sitagliptin intermediate - Google Patents

A kind of preparation method of sitagliptin intermediate Download PDF

Info

Publication number
CN107011138B
CN107011138B CN201710254023.9A CN201710254023A CN107011138B CN 107011138 B CN107011138 B CN 107011138B CN 201710254023 A CN201710254023 A CN 201710254023A CN 107011138 B CN107011138 B CN 107011138B
Authority
CN
China
Prior art keywords
trifluorophenylacetaldehyde
reaction
solvent
acid
acetone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710254023.9A
Other languages
Chinese (zh)
Other versions
CN107011138A (en
Inventor
潘庆华
周熹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hankuo Biological Co ltd
Original Assignee
Jiangsu Hankuo Biological Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hankuo Biological Co ltd filed Critical Jiangsu Hankuo Biological Co ltd
Priority to CN201710254023.9A priority Critical patent/CN107011138B/en
Publication of CN107011138A publication Critical patent/CN107011138A/en
Application granted granted Critical
Publication of CN107011138B publication Critical patent/CN107011138B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/0825Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/0827Syntheses with formation of a Si-C bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种西他列汀中间体VI的制备方法。所述方法以2,4,5‑三氟苯乙醛和丙酮为原料,在L‑脯氨酸的诱导催化下发生不对称Aldol反应,继而经羟基保护、Baeyer‑Villiger反应和脱保护及酯水解得到中间体VI。所述方法原料价格低廉易得、成本低、合成步骤少、反应条件温和且环境友好,立体选择性高,可用于工业化生产。

Figure DDA0001272868100000011
The invention discloses a preparation method of a sitagliptin intermediate VI. The method uses 2,4,5-trifluorophenylacetaldehyde and acetone as raw materials, and an asymmetric Aldol reaction occurs under the induction and catalysis of L-proline, followed by hydroxyl protection, Baeyer-Villiger reaction and deprotection and esterification Hydrolysis affords intermediate VI. The method has the advantages of low price and easy availability of raw materials, low cost, few synthesis steps, mild reaction conditions and environmental friendliness, high stereoselectivity, and can be used for industrial production.
Figure DDA0001272868100000011

Description

一种西他列汀中间体的制备方法A kind of preparation method of sitagliptin intermediate

技术领域technical field

本发明属于医药化工领域,具体涉及一种糖尿病用药西他列汀中间体的制备方法。The invention belongs to the field of medicine and chemical industry, and in particular relates to a preparation method of an intermediate for diabetes drug sitagliptin.

背景技术Background technique

西他列汀(Sitagliptin)是一种重要的糖尿病用药,具有明确显著的临床效果和用药安全性,是目前及未来治疗糖尿病的重磅药物之一,对于这一重要药物的合成,目前主要有以下四条路线。Sitagliptin is an important diabetes drug with clear and significant clinical effects and drug safety. It is one of the current and future blockbuster drugs for the treatment of diabetes. For the synthesis of this important drug, there are currently The following four routes.

路线一:Route one:

Figure BDA0001272868090000011
Figure BDA0001272868090000011

该路线是默克公司最早研发的制备路线,由于该路线中所用到不少昂贵的试剂,反应条件比较苛刻,且中间体分离困难,因此,该路线并不适用于大规模生产。This route is the earliest preparation route developed by Merck. Since many expensive reagents are used in this route, the reaction conditions are relatively harsh, and the separation of intermediates is difficult. Therefore, this route is not suitable for large-scale production.

路线二:Route two:

Figure BDA0001272868090000021
Figure BDA0001272868090000021

相比较于路线一,该路线的原料成本有了较大幅度的下降,可操作性也获得了较大的提升,但在关键的不对称催化步骤,所用到的配体和贵金属还是对成本产生了较大的影响。并且在本路线第一步反应中,还需使用无水无氧环境及加压氢气气氛,亦使成本增加,并大大降低了规模产业化的可操作性(Org.Proc.Res.Dev,2005 9(5)634-639.)。Compared with Route 1, the raw material cost of this route has been greatly reduced, and the operability has also been greatly improved. However, in the key asymmetric catalytic step, the ligands and precious metals used still contribute to the cost. greater impact. And in the first step reaction of this route, it is also necessary to use an anhydrous and oxygen-free environment and a pressurized hydrogen atmosphere, which also increases the cost and greatly reduces the operability of large-scale industrialization (Org.Proc.Res.Dev, 2005 9(5) 634-639.).

路线三:Route three:

Figure BDA0001272868090000031
Figure BDA0001272868090000031

该路线是默克公司所开发,其明显的缺陷是不对称催化的催化剂以及双键加氢用到氧化铂作催化剂都很昂贵,且中间体的稳定性差,质量稳定差,从而导致操作空间变小。This route was developed by Merck, and its obvious drawback is that the catalyst for asymmetric catalysis and the use of platinum oxide as a catalyst for hydrogenation of double bonds are expensive, and the stability of the intermediate is poor and the quality is poor, resulting in a change in operating space. Small.

路线四route four

Figure BDA0001272868090000041
Figure BDA0001272868090000041

该路线是2005年默克公司公开的新路线,特点是采用二茂铁配体的手性铑为催化剂,该催化剂高效且价格不高,但由于配体具有较高的不稳定性,反应必需在无氧无水的体系中进行,这使得在大规模使用时产生了较大的难度。This route is a new route disclosed by Merck in 2005. It is characterized by using chiral rhodium of ferrocene ligand as the catalyst. The catalyst is highly efficient and inexpensive. However, due to the high instability of the ligand, the reaction must be It is carried out in an oxygen-free and anhydrous system, which makes it difficult to use it on a large scale.

在西他列汀的制备中,(S)-(2,4,5-三氟苯基)-3-羟基-丁酸(VI)是一种非常重要的中间体。但如前文路线二所示,现有的(S)-(2,4,5-三氟苯基)-3-羟基-丁酸制备方法存在多种缺陷,大大制约了其规模化生产。In the preparation of sitagliptin, (S)-(2,4,5-trifluorophenyl)-3-hydroxy-butyric acid (VI) is a very important intermediate. However, as shown in Route 2 above, the existing method for preparing (S)-(2,4,5-trifluorophenyl)-3-hydroxy-butyric acid has many defects, which greatly restrict its large-scale production.

发明内容SUMMARY OF THE INVENTION

针对现有技术中已存在的上述问题,本发明公开了一种新的西他列汀中间体VI的制备方法,通过以下技术方案实施:In view of the above-mentioned problems existing in the prior art, the present invention discloses a new preparation method of sitagliptin intermediate VI, which is implemented by the following technical solutions:

Figure BDA0001272868090000051
Figure BDA0001272868090000051

提供了一种西他列汀中间体VI的制备方法,包括的步骤为:A preparation method of sitagliptin intermediate VI is provided, comprising the steps of:

1)将2,4,5-三氟苯乙醛II和丙酮溶解于溶剂中,在L-脯氨酸的诱导催化下发生不对称Aldol反应,生成手性中间体III;1) Dissolving 2,4,5-trifluorophenylacetaldehyde II and acetone in a solvent, under the induction and catalysis of L-proline, an asymmetric Aldol reaction occurs to generate a chiral intermediate III;

2)将手性中间体III和羟基保护剂以及任选的碱性助剂在非质子性溶剂中反应,保护羟基生成中间体IV;2) react chiral intermediate III with hydroxyl protecting agent and optional basic auxiliary agent in aprotic solvent to protect hydroxyl to generate intermediate IV;

3)使中间体IV在过氧化物体系中发生Baeyer-Villiger氧化反应,生成中间体V;3) Baeyer-Villiger oxidation reaction is generated in intermediate IV in peroxide system to generate intermediate V;

4)脱除羟基保护基同时水解,而后中和从而生成中间体VI。4) Removal of the hydroxyl protecting group and simultaneous hydrolysis followed by neutralization to generate intermediate VI.

优选地,步骤1)中所述2,4,5-三氟苯乙醛与丙酮、溶剂、L-脯氨酸的摩尔比1:(4~6):(17~23):(1~1.5)。Preferably, the molar ratio of 2,4,5-trifluorophenylacetaldehyde to acetone, solvent and L-proline described in step 1) is 1:(4~6):(17~23):(1~ 1.5).

优选地,步骤1)中所述溶剂是短链醇类化合物,优选乙醇;所述不对称Aldol反应在-40~-50℃的温度下进行,反应时间为6~10h,优选8h。Preferably, the solvent in step 1) is a short-chain alcohol compound, preferably ethanol; the asymmetric Aldol reaction is carried out at a temperature of -40 to -50°C, and the reaction time is 6 to 10 h, preferably 8 h.

优选地,步骤3)中所述Baeyer-Villiger氧化反应在40~60℃的温度,优选50℃的温度下进行;反应时间为2~3小时,优选2小时。Preferably, the Baeyer-Villiger oxidation reaction in step 3) is carried out at a temperature of 40-60° C., preferably at a temperature of 50° C.; the reaction time is 2-3 hours, preferably 2 hours.

优选地,步骤3)中所述过氧化物体系为过氧化氢水溶液、乙酸体系,其中所述过氧化氢水溶液中H2O2的质量浓度为20~50wt%,优选30wt%;所述2,4,5-三氟苯乙醛、过氧化氢水溶液、乙酸的摩尔比为1:(2.5~5.5):(8~12)。Preferably, the peroxide system in step 3) is an aqueous hydrogen peroxide solution and an acetic acid system, wherein the mass concentration of H 2 O 2 in the aqueous hydrogen peroxide solution is 20-50 wt %, preferably 30 wt %; the 2 The molar ratio of ,4,5-trifluorophenylacetaldehyde, aqueous hydrogen peroxide solution and acetic acid is 1:(2.5~5.5):(8~12).

优选地,步骤2)中所述2,4,5-三氟苯乙醛与羟基保护剂的摩尔比为1:(1~1.3);所述2,4,5-三氟苯乙醛与任选的碱性助剂的摩尔比为1:(1~1.3);优选所述碱性助剂为吡啶。Preferably, in step 2), the molar ratio of 2,4,5-trifluorophenylacetaldehyde to hydroxyl protective agent is 1:(1-1.3); the 2,4,5-trifluorophenylacetaldehyde and The molar ratio of the optional alkaline auxiliary agent is 1:(1-1.3); preferably, the alkaline auxiliary agent is pyridine.

优选地,步骤2)中所述羟基保护基为叔丁基二甲基氯硅烷;优选所述非质子性溶剂为乙酸乙酯、甲苯、氯苯和氯仿,更优选为乙酸乙酯。Preferably, the hydroxyl protecting group in step 2) is tert-butyldimethylchlorosilane; preferably, the aprotic solvent is ethyl acetate, toluene, chlorobenzene and chloroform, more preferably ethyl acetate.

优选地,步骤4)中脱除羟基保护基的步骤在酸性条件下于溶剂中进行;优选通过加入酸产生所述酸性条件;优选所述酸为盐酸、乙酸、硫酸、氯磺酸,更优选盐酸,最优选浓盐酸;所述酸的加入量按摩尔计为2,4,5-三氟苯乙醛的1.5-3倍。Preferably, the step of removing the hydroxyl protecting group in step 4) is carried out in a solvent under acidic conditions; the acidic conditions are preferably generated by adding an acid; preferably the acid is hydrochloric acid, acetic acid, sulfuric acid, chlorosulfonic acid, more preferably Hydrochloric acid, most preferably concentrated hydrochloric acid; the added amount of the acid is 1.5-3 times that of 2,4,5-trifluorophenylacetaldehyde in moles.

优选地,步骤4)中所述溶剂为丙酮,所述丙酮与2,4,5-三氟苯乙醛的摩尔比为2.5-3.5。Preferably, the solvent in step 4) is acetone, and the molar ratio of the acetone to 2,4,5-trifluorophenylacetaldehyde is 2.5-3.5.

本发明所称“任选的”指包含或者不包含的情况,例如“任选的碱性助剂”指包含碱性助剂的技术方案,或者不包含碱性助剂的技术方案。The term "optional" in the present invention refers to the case of inclusion or exclusion, for example, "optional alkaline auxiliary agent" refers to the technical solution including alkaline auxiliary agent, or the technical solution not including alkaline auxiliary agent.

本发明所称的短链醇类化合物指具有1~7个碳原子的醇类化合物。The short-chain alcohol compounds referred to in the present invention refer to alcohol compounds having 1 to 7 carbon atoms.

本发明所述的浓盐酸是质量分数为36~40%的盐酸水溶液。The concentrated hydrochloric acid of the present invention is an aqueous hydrochloric acid solution with a mass fraction of 36-40%.

本发明所述的羟基保护及脱保护反应可使用本领域的常规技术方法进行,优选羟基保护反应的反应温度为-5~5℃,反应时间1.5-3h。The hydroxyl protection and deprotection reactions of the present invention can be carried out using conventional technical methods in the art. Preferably, the reaction temperature of the hydroxyl protection reaction is -5-5°C, and the reaction time is 1.5-3h.

本发明所述的水解、中和反应可使用本领域的常规技术方法进行,优选地,步骤4)中所述中和步骤通过加入本领域常规使用的碱进行,优选所述碱为氢氧化钠。The hydrolysis and neutralization reactions of the present invention can be carried out using conventional technical methods in the art, preferably, the neutralization step in step 4) is carried out by adding a conventionally used alkali in the art, preferably the alkali is sodium hydroxide .

本发明的有益效果在于:The beneficial effects of the present invention are:

1)温和的反应条件1) Mild reaction conditions

本发明的方法不涉及无水无氧反应条件及加压操作(即各步骤均在常压下操作),反应条件更为温和,易于实施。The method of the present invention does not involve anhydrous and oxygen-free reaction conditions and pressurized operation (that is, each step is operated under normal pressure), and the reaction conditions are milder and easy to implement.

2)高效、低成本的反应方法2) Efficient and low-cost reaction method

传统方法中,从三氟苯乙醛出发制备目标中间体产品往往需要五步以上的反应过程;本发明的方法路线简单,从三氟苯乙醛出发,只需四步反应即可得到目标产品,提高了生产效率,减少原料损失。且本发明关键反应步骤中使用的原料L-脯氨酸为手性诱导试剂,价格低廉,相对于路线2所用催化剂的配体和贵金属,在成本上有极其显著的降低。In the traditional method, the preparation of the target intermediate product from trifluorophenylacetaldehyde often requires a reaction process of more than five steps; the method route of the present invention is simple, and starting from trifluorophenylacetaldehyde, the target product can be obtained by only four steps of reaction , improve the production efficiency and reduce the loss of raw materials. In addition, the raw material L-proline used in the key reaction steps of the present invention is a chirality inducing reagent, and the price is low. Compared with the ligands and precious metals of the catalyst used in route 2, the cost is extremely significantly reduced.

3)环境友好3) Environmentally friendly

本发明方法中反应步数减少,所用试剂量亦随之减少,降低了由试剂引发污染的可能性,且反应中不涉及气体的使用,减少了三废排放。In the method of the invention, the number of reaction steps is reduced, the amount of reagents used is also reduced, the possibility of pollution caused by the reagents is reduced, the use of gas is not involved in the reaction, and the discharge of three wastes is reduced.

4)更高的产品纯度4) Higher product purity

根据本发明方法制备的西他列汀中间体具有更高的ee值(95%及以上)。The sitagliptin intermediate prepared according to the method of the present invention has a higher ee value (95% and above).

具体实施方式Detailed ways

本发明所用试剂均为市售,规格为化学纯,其中主要原料的来源为:The reagents used in the present invention are all commercially available, and the specifications are chemically pure, and the sources of the main raw materials are:

L-脯氨酸,分析纯,500g,上海司信生物科技有限公司;L-Proline, analytical grade, 500g, Shanghai Sixin Biotechnology Co., Ltd.;

2,4,5-三氟苯乙醛,分析纯,150g,杭州尚杰化工有限公司;2,4,5-Trifluorophenylacetaldehyde, analytical grade, 150g, Hangzhou Shangjie Chemical Co., Ltd.;

过氧化氢水溶液,30wt%,杭州精欣化工有限公司。Aqueous hydrogen peroxide solution, 30wt%, Hangzhou Jingxin Chemical Co., Ltd.

本发明实施例所使用的仪器为:The instruments used in the embodiments of the present invention are:

1H NMR波谱仪,Varian 400MR; 1 H NMR spectrometer, Varian 400MR;

质谱仪,Agilent 5975E;Mass spectrometer, Agilent 5975E;

显微熔点仪RT3-03C;SGW-2自动旋光仪,上海精密仪器仪表有限公司;Micro melting point apparatus RT3-03C; SGW-2 automatic polarimeter, Shanghai Precision Instrument Co., Ltd.;

气相色谱(GC)仪:Agilent 7890A。Gas Chromatograph (GC) Apparatus: Agilent 7890A.

实施例1Example 1

步骤1.(S)-(2,4,5-三氟苯基)-3-羟基-戊酮(化合物III)的制备:Step 1. Preparation of (S)-(2,4,5-trifluorophenyl)-3-hydroxy-pentanone (Compound III):

将298g丙酮、800g乙醇、115g L-脯氨酸加入反应瓶中,搅拌溶解后,缓慢降温至-40~-50℃,滴加174.1g 2,4,5-三氟苯乙醛,约两小时滴完,继续反应约8小时,气相色谱GC监测至2,4,5-三氟苯乙醛体系含量小于1%,体系升温至-5℃,加入600ml水和700ml乙酸乙酯,分出有机层,加入硫酸镁干燥,过滤,所得滤液扣除溶剂乙酸乙酯后化合物III的GC检测纯度为94%,直接用于下一步反应。Add 298g of acetone, 800g of ethanol, and 115g of L-proline into the reaction flask, stir and dissolve, slowly cool down to -40~-50℃, add 174.1g of 2,4,5-trifluorophenylacetaldehyde dropwise, about two After dripping for 8 hours, the reaction was continued for about 8 hours. The 2,4,5-trifluorophenylacetaldehyde system content was monitored by gas chromatography to be less than 1%. The organic layer was dried by adding magnesium sulfate, and filtered. The obtained filtrate, after deducting the solvent ethyl acetate, had a GC detection purity of 94% of compound III, which was directly used in the next reaction.

步骤2.(S)-(2,4,5-三氟苯基)-3-叔丁基二甲基硅氧基-丁酮(化合物IV)的制备:Step 2. Preparation of (S)-(2,4,5-trifluorophenyl)-3-tert-butyldimethylsiloxy-butanone (Compound IV):

将步骤1所得乙酸乙酯溶液降温至0℃,加入吡啶79.0g,搅拌下滴加叔丁基二甲基氯硅烷151.0g,保持体系温度不超过5℃,继续反应2小时,过滤去除生成的吡啶盐酸盐,不高于35℃减压蒸出溶剂,所剩淡黄色油状化合物IV经GC检测纯度为95%,直接用于下步反应。The ethyl acetate solution obtained in step 1 was cooled to 0 °C, 79.0 g of pyridine was added, 151.0 g of tert-butyldimethylsilyl chloride was added dropwise with stirring, and the temperature of the system was kept not higher than 5 °C, the reaction was continued for 2 hours, and the generated chloroform was removed by filtration. Pyridine hydrochloride, the solvent was evaporated under reduced pressure not higher than 35°C, and the remaining pale yellow oily compound IV was 95% pure as detected by GC, which was directly used in the next step.

步骤3.(S)-(2,4,5-三氟苯基)-3-叔丁基二甲基硅氧基-丁酸甲酯(化合物V)的制备:Step 3. Preparation of (S)-(2,4,5-trifluorophenyl)-3-tert-butyldimethylsiloxy-butyric acid methyl ester (compound V):

将步骤2中所得的油状物加入到600ml乙酸中,搅拌下升温至50℃,缓慢滴加30%的过氧化氢水溶液350ml,反应两小时后,不超过50℃减压蒸除乙酸,剩余油状物不纯化直接用于下步反应。The oil obtained in step 2 was added to 600 ml of acetic acid, and the temperature was raised to 50 ° C under stirring, and 350 ml of 30% aqueous hydrogen peroxide solution was slowly added dropwise. The material was directly used in the next step without purification.

步骤4.(S)-(2,4,5-三氟苯基)-3-羟基-丁酸(化合物VI)的制备:Step 4. Preparation of (S)-(2,4,5-trifluorophenyl)-3-hydroxy-butyric acid (Compound VI):

将步骤3所得油状物加入500ml 15%的盐酸和200ml丙酮中,55℃左右搅拌24小时,TLC监测至原料点消失,即反应完毕后,加入40%氢氧化钠水溶液调节pH至中性。减压蒸馏溶剂至内温40~45℃,再加400ml水、500ml甲基叔丁基醚萃取,分出有机层,减压蒸出甲基叔丁基醚,体系加入230ml甲苯,0℃下析晶8小时,过滤、烘干,得类白色结晶113g,以2,4,5-三氟苯乙醛计收率48%,熔点:82-83℃,ee值为95%,[α]D=6.94°(C=1.0,CHCl3),1HNMR(400Mz,CDCl3):7.1(m 1H),6.16(m,1H),4.28(m1H),2.82(d 2H),2.60(dd 1H),2.55(dd 1H)。The oil obtained in step 3 was added to 500ml of 15% hydrochloric acid and 200ml of acetone, stirred at about 55°C for 24 hours, and monitored by TLC until the starting point disappeared, that is, after the reaction was completed, 40% aqueous sodium hydroxide solution was added to adjust pH to neutrality. The solvent was distilled under reduced pressure to an internal temperature of 40-45°C, then 400ml of water and 500ml of methyl tert-butyl ether were added for extraction, the organic layer was separated, and the methyl tert-butyl ether was evaporated under reduced pressure. Crystallize for 8 hours, filter and dry to obtain 113 g of off-white crystals, yield 48% based on 2,4,5-trifluorophenylacetaldehyde, melting point: 82-83°C, ee value 95%, [α] D = 6.94° (C=1.0, CHCl 3 ), 1 H NMR (400Mz, CDCl 3 ): 7.1 (m 1H), 6.16 (m, 1H), 4.28 (m 1H), 2.82 (d 2H), 2.60 (dd 1H ), 2.55 (dd 1H).

实施例2Example 2

步骤1.(S)-(2,4,5-三氟苯基)-3-羟基-戊酮(化合物III)的制备:Step 1. Preparation of (S)-(2,4,5-trifluorophenyl)-3-hydroxy-pentanone (Compound III):

将298g丙酮、1000g乙醇、170g L-脯氨酸加入反应瓶中,搅拌溶解后,缓慢降温至-40--50℃,滴加174.1g 2,4,5-三氟苯乙醛,约两小时滴完,继续反应约10小时,GC监测至2,4,5-三氟苯乙醛体系含量小于1%,体系升温至-5℃,加入600ml水和700ml乙酸乙酯,分出有机层,加入硫酸镁干燥,过滤,所得滤液扣除溶剂乙酸乙酯后化合物III的GC检测纯度95%,直接用于下一步反应。Add 298g acetone, 1000g ethanol, 170g L-proline into the reaction flask, stir to dissolve, slowly cool down to -40--50°C, drop 174.1g 2,4,5-trifluorophenylacetaldehyde, about two After dripping for 1 hour, the reaction was continued for about 10 hours. GC monitoring showed that the content of the 2,4,5-trifluorophenylacetaldehyde system was less than 1%, the temperature of the system was -5 °C, 600 ml of water and 700 ml of ethyl acetate were added, and the organic layer was separated. , adding magnesium sulfate to dry, and filtering, the obtained filtrate, after deducting the solvent ethyl acetate, has a GC detection purity of 95% of compound III, which is directly used in the next reaction.

步骤2~4.Steps 2 to 4.

除将起始反应物替换为本实施例步骤1的产物外,其余步骤均按实施例1的步骤2~4进行。Except for replacing the starting reactant with the product of step 1 of this example, the remaining steps are carried out according to steps 2 to 4 of embodiment 1.

最终得类白色结晶105g,以2,4,5-三氟苯乙醛计收率45%,熔点:82-83℃,ee值为95%,[α]D=6.94°(C=1.0,CHCl3),1H NMR(400Mz,CDCl3):7.1(m 1H),6.16(m,1H),4.28(m1H),2.82(d 2H),2.60(dd 1H),2.55(dd 1H)。Finally, 105 g of off-white crystals were obtained, with a yield of 45% based on 2,4,5-trifluorophenylacetaldehyde, melting point: 82-83 °C, ee value of 95%, [α] D = 6.94 ° (C = 1.0, CHCl 3 ), 1 H NMR (400 Mz, CDCl 3 ): 7.1 (m 1H), 6.16 (m, 1H), 4.28 (m 1H), 2.82 (d 2H), 2.60 (dd 1H), 2.55 (dd 1H).

实施例3Example 3

将240g丙酮、700g甲醇、140g L-脯氨酸加入反应瓶中,搅拌溶解后,缓慢降温至-45--50℃,滴加174.1g 2,4,5-三氟苯乙醛,约两小时滴完,继续反应约10小时,GC监测至2,4,5-三氟苯乙醛体系含量小于1%,体系升温至-5℃,加入500ml水和700ml乙酸乙酯,分出有机层,加入硫酸镁干燥,过滤,所得滤液扣除溶剂乙酸乙酯后化合物III的GC检测纯度94%,直接用于下一步反应。Add 240g acetone, 700g methanol, and 140g L-proline into the reaction flask, stir to dissolve, slowly cool down to -45--50°C, drop 174.1g 2,4,5-trifluorophenylacetaldehyde, about two After dripping for 10 hours, the reaction was continued for about 10 hours. GC monitoring showed that the content of the 2,4,5-trifluorophenylacetaldehyde system was less than 1%. The system was heated to -5 °C, 500 ml of water and 700 ml of ethyl acetate were added, and the organic layer was separated. , adding magnesium sulfate to dry, filtering, the obtained filtrate after deducting the solvent ethyl acetate, the GC detection purity of compound III is 94%, which is directly used in the next reaction.

步骤2~4.Steps 2 to 4.

除将起始反应物替换为本实施例步骤1的产物外,其余步骤均按实施例1的步骤2~4进行。Except for replacing the starting reactant with the product of step 1 of this example, the remaining steps are carried out according to steps 2 to 4 of embodiment 1.

最终得类白色结晶110g,以2,4,5-三氟苯乙醛计收率47%,熔点:82-83℃,ee值为95%,[α]D=6.93°(C=1.0,CHCl3),1H NMR(400Mz,CDCl3):7.1(m 1H),6.16(m,1H),4.28(m1H),2.82(d 2H),2.60(dd 1H),2.55(dd 1H)。Finally, 110 g of off-white crystals were obtained, with a yield of 47% based on 2,4,5-trifluorophenylacetaldehyde, melting point: 82-83°C, ee value of 95%, [α] D = 6.93° (C = 1.0, CHCl 3 ), 1 H NMR (400 Mz, CDCl 3 ): 7.1 (m 1H), 6.16 (m, 1H), 4.28 (m 1H), 2.82 (d 2H), 2.60 (dd 1H), 2.55 (dd 1H).

Claims (18)

1.一种西他列汀中间体VI的制备方法,包括的步骤为:1. a preparation method of sitagliptin intermediate VI, the step that comprises is: 1)将2,4,5-三氟苯乙醛II和丙酮溶解于溶剂中,在L-脯氨酸的诱导催化下发生不对称Aldol反应,生成手性中间体III;1) Dissolving 2,4,5-trifluorophenylacetaldehyde II and acetone in a solvent, under the induction and catalysis of L-proline, an asymmetric Aldol reaction occurs to generate a chiral intermediate III;
Figure FDA0002391766040000011
Figure FDA0002391766040000011
2)将手性中间体III和羟基保护剂以及任选的碱性助剂在非质子性溶剂中反应,保护羟基生成中间体IV;2) react chiral intermediate III with hydroxyl protecting agent and optional basic auxiliary agent in aprotic solvent to protect hydroxyl to generate intermediate IV;
Figure FDA0002391766040000012
Figure FDA0002391766040000012
3)使中间体IV在过氧化物体系中发生Baeyer-Villiger氧化反应,生成中间体V;3) Baeyer-Villiger oxidation reaction is generated in intermediate IV in peroxide system to generate intermediate V;
Figure FDA0002391766040000013
Figure FDA0002391766040000013
4)脱除羟基保护基同时水解,而后进行中和反应,从而生成中间体VI,4) remove hydroxyl protecting group and hydrolyze simultaneously, then carry out neutralization reaction, thereby generate intermediate VI,
Figure FDA0002391766040000014
Figure FDA0002391766040000014
2.根据权利要求1所述的方法,其特征在于,步骤1)中所述2,4,5-三氟苯乙醛与丙酮、溶剂、L-脯氨酸的摩尔比为=1:(4~6):(17~23):(1~1.5)。2. method according to claim 1 is characterized in that, the mol ratio of 2,4,5-trifluorophenylacetaldehyde described in step 1) and acetone, solvent, L-proline is=1:( 4~6):(17~23):(1~1.5). 3.根据权利要求1所述的方法,其特征在于,步骤1)中所述溶剂是短链醇类化合物;所述不对称Aldol反应在-40~-50℃的温度下进行,反应时间为6~10h。3. The method according to claim 1, wherein the solvent in step 1) is a short-chain alcohol compound; the asymmetric Aldol reaction is carried out at a temperature of -40 to -50 °C, and the reaction time is 6 ~ 10h. 4.根据权利要求3所述的方法,其特征在于,步骤1)中所述溶剂是乙醇。4. The method according to claim 3, wherein the solvent described in step 1) is ethanol. 5.根据权利要求3所述的方法,其特征在于,步骤1)中所述不对称Aldol反应的反应时间为8h。5. The method according to claim 3, wherein the reaction time of the asymmetric Aldol reaction described in step 1) is 8h. 6.根据权利要求1所述的方法,其特征在于,步骤3)中所述Baeyer-Villiger氧化反应在40~60℃的温度下进行;反应时间为2~3小时。6 . The method according to claim 1 , wherein the Baeyer-Villiger oxidation reaction in step 3) is carried out at a temperature of 40-60° C.; the reaction time is 2-3 hours. 7 . 7.根据权利要求6所述的方法,其特征在于,步骤3)中所述Baeyer-Villiger氧化反应在50℃的温度下进行。7. The method according to claim 6, wherein the Baeyer-Villiger oxidation reaction described in step 3) is carried out at a temperature of 50°C. 8.根据权利要求1所述的方法,其特征在于,步骤3)中所述过氧化物体系为过氧化氢水溶液、乙酸体系,其中所述过氧化氢水溶液中H2O2浓度为20~50wt%;所述2,4,5-三氟苯乙醛、过氧化氢水溶液、乙酸的摩尔比为1:(2.5~5.5):(8~12)。8. The method according to claim 1, wherein the peroxide system in step 3) is an aqueous hydrogen peroxide solution and an acetic acid system, wherein the H2O2 concentration in the aqueous hydrogen peroxide solution is 20 ~20 50wt%; the molar ratio of the 2,4,5-trifluorophenylacetaldehyde, the aqueous hydrogen peroxide solution and the acetic acid is 1:(2.5-5.5):(8-12). 9.根据权利要求8所述的方法,其特征在于,所述过氧化氢水溶液中H2O2浓度为30wt%。9 . The method according to claim 8 , wherein the concentration of H 2 O 2 in the aqueous hydrogen peroxide solution is 30 wt %. 10 . 10.根据权利要求1所述的方法,其特征在于,步骤2)中所述2,4,5-三氟苯乙醛与羟基保护剂的摩尔比为1:(1~1.3);所述2,4,5-三氟苯乙醛与任选的碱性助剂的摩尔比为1:(1~1.3)。10. The method according to claim 1, wherein the molar ratio of 2,4,5-trifluorophenylacetaldehyde to hydroxyl protective agent in step 2) is 1:(1~1.3); the The molar ratio of 2,4,5-trifluorophenylacetaldehyde to the optional alkaline auxiliary agent is 1:(1-1.3). 11.根据权利要求1或10所述的方法,其特征在于,步骤2)中所述碱性助剂为吡啶。11. The method according to claim 1 or 10, characterized in that, in step 2), the basic auxiliary agent is pyridine. 12.根据权利要求1所述的方法,其特征在于,步骤2)中所述羟基保护基为叔丁基二甲基氯硅烷;所述非质子性溶剂为乙酸乙酯、甲苯、氯苯和氯仿。12. The method according to claim 1, wherein the hydroxyl protecting group in step 2) is tert-butyldimethylsilyl chloride; the aprotic solvent is ethyl acetate, toluene, chlorobenzene and Chloroform. 13.根据权利要求1所述的方法,其特征在于,步骤4)中脱除羟基保护基的步骤在酸性条件下于溶剂中进行。13. The method according to claim 1, wherein the step of removing the hydroxyl protecting group in step 4) is carried out in a solvent under acidic conditions. 14.根据权利要求13所述的方法,其特征在于,通过加入酸产生所述酸性条件,所述酸的加入量按摩尔计为2,4,5-三氟苯乙醛的1.5-3倍。14. The method according to claim 13, wherein the acidic condition is generated by adding an acid, and the amount of the acid added is 1.5-3 times that of 2,4,5-trifluorophenylacetaldehyde in moles . 15.根据权利要求14所述的方法,其特征在于,所述酸为盐酸、乙酸、硫酸、氯磺酸。15. The method according to claim 14, wherein the acid is hydrochloric acid, acetic acid, sulfuric acid, and chlorosulfonic acid. 16.根据权利要求13-15任一项所述的方法,其特征在于,步骤4)中所述溶剂为丙酮,所述丙酮与2,4,5-三氟苯乙醛的摩尔比为2.5-3.5。16. The method according to any one of claims 13-15, wherein the solvent in step 4) is acetone, and the molar ratio of the acetone to 2,4,5-trifluorophenylacetaldehyde is 2.5 -3.5. 17.根据权利要求1所述的方法,其特征在于,步骤4)中所述中和步骤通过加入碱进行。17. The method according to claim 1, wherein the neutralization step in step 4) is performed by adding alkali. 18.根据权利要求17所述的方法,其特征在于,所述碱为氢氧化钠。18. The method of claim 17, wherein the alkali is sodium hydroxide.
CN201710254023.9A 2017-04-18 2017-04-18 A kind of preparation method of sitagliptin intermediate Active CN107011138B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710254023.9A CN107011138B (en) 2017-04-18 2017-04-18 A kind of preparation method of sitagliptin intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710254023.9A CN107011138B (en) 2017-04-18 2017-04-18 A kind of preparation method of sitagliptin intermediate

Publications (2)

Publication Number Publication Date
CN107011138A CN107011138A (en) 2017-08-04
CN107011138B true CN107011138B (en) 2020-07-21

Family

ID=59447365

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710254023.9A Active CN107011138B (en) 2017-04-18 2017-04-18 A kind of preparation method of sitagliptin intermediate

Country Status (1)

Country Link
CN (1) CN107011138B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103755596A (en) * 2013-09-30 2014-04-30 浙江工业大学 Preparation method of sitagliptin intermediate
CN103819475A (en) * 2014-02-11 2014-05-28 浙江新和成股份有限公司 Synthetic method of sitagliptin and salt thereof
CN105968030A (en) * 2016-05-10 2016-09-28 浙江工业大学 Preparation method of Sitagliptin midbody of beta-amino acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158265A1 (en) * 2010-08-27 2013-06-20 Dhananjay Govind Sathe Sitagliptin, salts and polymorphs thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103755596A (en) * 2013-09-30 2014-04-30 浙江工业大学 Preparation method of sitagliptin intermediate
CN103819475A (en) * 2014-02-11 2014-05-28 浙江新和成股份有限公司 Synthetic method of sitagliptin and salt thereof
CN105968030A (en) * 2016-05-10 2016-09-28 浙江工业大学 Preparation method of Sitagliptin midbody of beta-amino acid

Also Published As

Publication number Publication date
CN107011138A (en) 2017-08-04

Similar Documents

Publication Publication Date Title
EP3712130B1 (en) Method for synthesis of roxadustat and intermediate compounds thereof
EP4169906B1 (en) Method for synthesis of roxadustat and intermediate thereof, and intermediate thereof
CN114395009B (en) A kind of synthesis method of high-purity cholesterol
KR20240135777A (en) Method for synthesizing high-purity plant-derived cholesterol
CN111559995B (en) A kind of preparation technology of ascorbic acid ethyl ether
CN107011138B (en) A kind of preparation method of sitagliptin intermediate
CN116497082B (en) Method for synthesizing 3 alpha, 7 alpha, 24R-trihydroxy cholesterol by chemical-enzymatic method
JP4425654B2 (en) Water-soluble transition metal-diamine complex, method for producing the same, and use thereof
CN103665084A (en) Method for preparing abiraterone acetate
CN101519393A (en) Novel method for preparing Scopoletin
CN102153611B (en) Method for synthesizing pregnenolol acetate and congener thereof
CN101343308B (en) Method for preparing 7 alpha-bromo steroid compound
CN111100042B (en) Preparation method of 2-methoxy-5-sulfonamide benzoic acid
KR100641825B1 (en) Method for producing 4-biphenylacetic acid
CN109134251B (en) A kind of preparation method of methyl 3-oxo-2-pentyl-cyclopentenyl acetate
CN106187837B (en) Florfenicol intermediate, preparation method thereof and preparation method of florfenicol
CN101648911B (en) Purifying method of 4-nitro-3,5-dimethylpyridine-N-oxide
CN117105862B (en) A method for preparing roxadustat and its intermediates
CN115304477B (en) Preparation method of aromatic carboxylic acid ester
CN114685410B (en) A kind of preparation method of butylphthalide
CN105646431B (en) Method for synthesizing marine natural product Puupehenone
CN110790657B (en) The synthetic method of 7-methyljuglone
CN102241729B (en) Synthetic method of 3-carbonyl-4-aza-5 alpha-androstane-17 beta-carboxylic acid methyl ester
CN103102261A (en) Synthesis method of spiro[2.5]octane-5-carboxylic acid
RU2494087C1 (en) Method of producing omega-iodo-aliphatic carboxylic acids and esters thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PP01 Preservation of patent right

Effective date of registration: 20250910

Granted publication date: 20200721

PP01 Preservation of patent right